LUCENTIS® (ranibizumab injection) is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab, which lacks an Fc region, has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline. Tetracycline is not detectable in the final product.

Possible side effects of Ranibizumab (Lucentis)?
  • vision changes;
  • eye pain, redness, or irritation;
  • discharge or bleeding from the eye;
  • increased eye sensitivity to light;
  • swelling around your eye;
  • seeing “stars” or flashes of light, especially in your peripheral (side) vision;
  • pain or burning when you urinate.
  • sudden numbness or… Abraxine - South Delhi Pharma enquiry_3